These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33629212)

  • 1. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
    Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
    Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
    Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
    J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
    Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
    Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 11. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
    Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
    Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.
    Weng J; Chen L; Liu H; Yang XP; Huang L
    Inflammation; 2022 Jun; 45(3):1146-1161. PubMed ID: 35064379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
    Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
    Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL6 inhibitor FX1 attenuates inflammatory responses in murine sepsis through strengthening BCL6 binding affinity to downstream target gene promoters.
    Zhang H; Qi X; Wu J; Huang X; Zhang A; Chen S; Ding X; Chen S; Le S; Zou Y; Xu H; Ye P; Xia J
    Int Immunopharmacol; 2019 Oct; 75():105789. PubMed ID: 31401377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
    Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
    Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
    El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
    Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
    Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
    Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL6 confers resistance to HDAC inhibitors in DLBCL.
    Fan G; Zhang Y; Li Q; Rong R; Chen S; He L; Li B; Zhuang W
    Biochem Pharmacol; 2024 Sep; 227():116466. PubMed ID: 39102989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.